Search Results - "LAM, Lloyd T"

Potential mechanisms of resistance to venetoclax and strategies to circumvent it by Tahir, Stephen K, Smith, Morey L, Hessler, Paul, Rapp, Lisa Roberts, Idler, Kenneth B, Park, Chang H, Leverson, Joel D, Lam, Lloyd T

“…Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted…”
Get full text

Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP by Wang, Rui, He, Yupeng, Robinson, Valerie, Yang, Ziping, Hessler, Paul, Lasko, Loren M, Lu, Xin, Bhathena, Anahita, Lai, Albert, Uziel, Tamar, Lam, Lloyd T

“…Metastatic melanoma is responsible for approximately 80% of deaths from skin cancer. Microphthalmia-associated transcription factor (MITF) is a…”
Get full text

A loss-of-function RNA interference screen for molecular targets in cancer by Powell, John, Yang, Liming, Lam, Lloyd T, Dave, Sandeep, Davis, R. Eric, Lenz, Georg, Zhao, Hong, Staudt, Louis M, Ngo, Vu N, Lamy, Laurence, Yu, Xin

“…The pursuit of novel therapeutic agents in cancer relies on the identification and validation of molecular targets. Hallmarks of cancer include…”
Get full text

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation by Guo, Jun, Lam, Lloyd T., Longenecker, Kenton L., Bui, Mai H., Idler, Kenneth B., Glaser, Keith B., Wilsbacher, Julie L., Tse, Chris, Pappano, William N., Huang, Tzu-Hsuan

“…Cancer cells have an unusually high requirement for the central and intermediary metabolite nicotinamide adenine dinucleotide (NAD+), and NAD+ depletion…”
Get full text

Small Molecule Inhibitors of IκB Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling by LAM, Lloyd T, DAVIS, R. Eric, STAUDT, Louis M, PIERCE, Jackie, HEPPERLE, Michael, YAJUN XU, HOTTELET, Maria, YUHUA NONG, DANYI WEN, ADAMS, Julian, DANG, Lenny

“…Constitutive activation of the NF-κB pathway is required for survival of the activated B cell–like (ABC) subgroup of diffuse large B-cell lymphoma (DLBCL)…”
Get full text

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression by Annunziata, Christina M., Hernandez, Lidia, Davis, R. Eric, Zingone, Adriana, Lamy, Laurence, Lam, Lloyd T., Hurt, Elaine M., Shaffer, Arthur L., Kuehl, W. Michael, Staudt, Louis M.

“…Modulating aberrant transcription of oncogenes is a relatively unexplored opportunity in cancer therapeutics. In approximately 10% of multiple myelomas, the…”
Get full text

A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax) by Lam, Lloyd T, Lu, Xin, Zhang, Haichao, Lesniewski, Rick, Rosenberg, Saul, Semizarov, Dimitri

“…Evasion of apoptosis is a known feature of cancer cells. One mechanism of deregulating the apoptotic pathway is through overexpression of antiapoptotic BCL2…”
Get full text

Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screen by Lam, Lloyd T, Davis, R. Eric, Ngo, Vu N, Lenz, Georg, Wright, George, Xu, Weihong, Zhao, Hong, Yu, Xin, Dang, Lenny, Staudt, Louis M

“…A subtype of diffuse large B-cell lymphoma (DLBCL), termed activated B-cell-like (ABC) DLBCL, depends on constitutive nuclear factor-κB (NF-κB) signaling for…”
Get full text

A library of gene expression signatures to illuminate normal and pathological lymphoid biology by Shaffer, Arthur L., Wright, George, Yang, Liming, Powell, John, Ngo, Vu, Lamy, Laurence, Lam, Lloyd T., Davis, R. Eric, Staudt, Louis M.

“…Genomics has provided a lever to pry open lymphoid cells and examine their regulatory biology. The large body of available gene expression data has also…”
Get full text

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients by Yuda, Junichiro, Will, Christine, Phillips, Darren C., Abraham, Linu, Alvey, Cory, Avigdor, Abraham, Buck, Wayne, Besenhofer, Lauren, Boghaert, Erwin, Cheng, Dong, Cojocari, Dan, Doyle, Kelly, Hansen, T. Matthew, Huang, Kevin, Johnson, Eric F., Judd, Andrew S., Judge, Russell A., Kalvass, John C., Kunzer, Aaron, Lam, Lloyd T., Li, Rachel, Martin, Ruth L., Mastracchio, Anthony, Mitten, Mike, Petrich, Adam, Wang, Jin, Ward, James E., Zhang, Haichao, Wang, Xilu, Wolff, Johannes E., Bell-McGuinn, Katherine M., Souers, Andrew J.

“…Background MCL-1 is a prosurvival B-cell lymphoma 2 family protein that plays a critical role in tumor maintenance and survival and can act as a resistance…”
Get full text

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol by Lam, L T, Pickeral, O K, Peng, A C, Rosenwald, A, Hurt, E M, Giltnane, J M, Averett, L M, Zhao, H, Davis, R E, Sathyamoorthy, M, Wahl, L M, Harris, E D, Mikovits, J A, Monks, A P, Hollingshead, M G, Sausville, E A, Staudt, L M

“…Flavopiridol, a flavonoid currently in cancer clinical trials, inhibits cyclin-dependent kinases (CDKs) by competitively blocking their ATP-binding pocket…”
Get full text

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours by Lasko, Loren M., Jakob, Clarissa G., Edalji, Rohinton P., Qiu, Wei, Montgomery, Debra, Digiammarino, Enrico L., Hansen, T. Matt, Risi, Roberto M., Frey, Robin, Manaves, Vlasios, Shaw, Bailin, Algire, Mikkel, Hessler, Paul, Lam, Lloyd T., Uziel, Tamar, Faivre, Emily, Ferguson, Debra, Buchanan, Fritz G., Martin, Ruth L., Torrent, Maricel, Chiang, Gary G., Karukurichi, Kannan, Langston, J. William, Weinert, Brian T., Choudhary, Chunaram, de Vries, Peter, Kluge, Arthur F., Patane, Michael A., Van Drie, John H., Wang, Ce, McElligott, David, Kesicki, Ed, Marmorstein, Ronen, Sun, Chaohong, Cole, Philip A., Rosenberg, Saul H., Michaelides, Michael R., Lai, Albert, Bromberg, Kenneth D.

“…A potent and selective catalytic inhibitor of p300/CBP histone acetyltransferases suppresses tumour proliferation across multiple cell lineages, illustrating…”
Get full text

MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer by Plotnik, Joshua P, Zha, Zheng, Feng, Weiguo, Lee, Irene, Riehm, Jacob, McClure, Ryan A, Sandoval, Stephanie, Uziel, Tamar, Murphy, Erin, Lu, Xin, Lam, Lloyd T

“…Small-cell lung cancer (SCLC) accounts for nearly 15% of all lung cancers. Although patients respond to first-line therapy readily, rapid relapse is…”
Get more information

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies by Bui, Mai H, Lin, Xiaoyu, Albert, Daniel H, Li, Leiming, Lam, Lloyd T, Faivre, Emily J, Warder, Scott E, Huang, Xiaoli, Wilcox, Denise, Donawho, Cherrie K, Sheppard, George S, Wang, Le, Fidanze, Steve, Pratt, John K, Liu, Dachun, Hasvold, Lisa, Uziel, Tamar, Lu, Xin, Kohlhapp, Fred, Fang, Guowei, Elmore, Steven W, Rosenberg, Saul H, McDaniel, Keith F, Kati, Warren M, Shen, Yu

“…ABBV-075 is a potent and selective BET family bromodomain inhibitor that recently entered phase I clinical trials. Comprehensive preclinical characterization…”
Get full text

Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors by Lam, Lloyd T, Lin, Xiaoyu, Faivre, Emily J, Yang, Ziping, Huang, Xiaoli, Wilcox, Denise M, Bellin, Richard J, Jin, Sha, Tahir, Stephen K, Mitten, Michael, Magoc, Terry, Bhathena, Anahita, Kati, Warren M, Albert, Daniel H, Shen, Yu, Uziel, Tamar

“…Ten percent to 15% of all lung cancers are small-cell lung cancer (SCLC). SCLC usually grows and metastasizes before it is diagnosed and relapses rapidly upon…”
Get full text

Statins enhance efficacy of venetoclax in blood cancers by Lee, J Scott, Roberts, Andrew, Juarez, Dennis, Vo, Thanh-Trang T, Bhatt, Shruti, Herzog, Lee-Or, Mallya, Sharmila, Bellin, Richard J, Agarwal, Suresh K, Salem, Ahmed Hamed, Xu, Tu, Jia, Jia, Li, Lingxiao, Hanna, John R, Davids, Matthew S, Fleischman, Angela G, O'Brien, Susan, Lam, Lloyd T, Leverson, Joel D, Letai, Anthony, Schatz, Jonathan H, Fruman, David A

“…Statins have shown promise as anticancer agents in experimental and epidemiologic research. However, any benefit that they provide is likely context-dependent,…”
Get more information

Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia by Zhang, Lu, Cai, Tianyu, Lin, Xiaoyu, Huang, Xiaoli, Bui, Mai H, Plotnik, Joshua P, Bellin, Richard J, Faivre, Emily J, Kuruvilla, Vinitha M, Lam, Lloyd T, Lu, Xin, Zha, Zheng, Feng, Weiguo, Hessler, Paul, Uziel, Tamar, Zhang, Qi, Cavazos, Antonio, Han, Lina, Ferguson, Debra C, Mehta, Gaurav, Shanmugavelandy, Sriram S, Magoc, Terrance J, Rowe, Jenny, Goodwin, Neal C, Dorritie, Kathleen A, Boyiadzis, Michael, Albert, Daniel H, McDaniel, Keith F, Kati, Warren M, Konopleva, Marina, Shen, Yu

“…Dual bromodomain BET inhibitors that bind with similar affinities to the first and second bromodomains across BRD2, BRD3, BRD4, and BRDT have displayed modest…”
Get full text

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways by Lenz, Georg, Wright, George W, Emre, N.C. Tolga, Kohlhammer, Holger, Dave, Sandeep S, Davis, R. Eric, Carty, Shannon, Lam, Lloyd T, Shaffer, A.L, Xiao, Wenming, Powell, John, Rosenwald, Andreas, Ott, German, Muller-Hermelink, Hans Konrad, Gascoyne, Randy D, Connors, Joseph M, Campo, Elias, Jaffe, Elaine S, Delabie, Jan, Smeland, Erlend B, Rimsza, Lisa M, Fisher, Richard I, Weisenburger, Dennis D, Chan, Wing C, Staudt, Louis M

“…Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B-cell lymphoma (DLBCL), termed germinal center B-cell-like (GCB)…”
Get full text

Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer by Zhang, Haichao, Xue, John, Hessler, Paul, Tahir, Stephen K, Chen, Jun, Jin, Sha, Souers, Andrew J, Leverson, Joel D, Lam, Lloyd T

“…Background Defects in programmed cell death, or apoptosis, are a hallmark of cancer. The anti-apoptotic B-cell lymphoma 2 (BCL-2) family proteins, including…”
Get full text

Design, Synthesis, and Biological Investigation of Thailanstatin A and Spliceostatin D Analogues Containing Tetrahydropyran, Tetrahydrooxazine, and Fluorinated Structural Motifs by Nicolaou, K. C, Rekula, Santhosh Reddy, Kumar, S. Mothish, Podilapu, Ananda Rao, Matuszak, Ryan P, Jung, Paul M, Lam, Lloyd T, Phillips, Andrew C, Lyssikatos, Joseph, Munneke, Stefan, Gu, Christine, Sarvaiya, Hetal, Sandoval, Joseph, Hammond, Mikhail, Aujay, Monette, Purcell, James W, Reilly, Regina M, Gavrilyuk, Julia

“…Thailanstatin A and spliceostatin D, two naturally occurring molecules endowed with potent antitumor activities by virtue of their ability to bind and inhibit…”
Get full text